Author:
Weringh G.,Komen B. J.,Thieme R. E.,Hoeven R. T. M.,Vos T.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy,General Medicine,Pharmacology (medical),Pharmacology
Reference20 articles.
1. Beresford R, Ward A. Haloperidol decanoate; a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987;33: 31–49.
2. Pakes GE. Haloperidol decanoate in perspective. In: Johnson DAW, editor. Haloperidol decanoate and the treatment of chronic schizophrenia. New York: Adis Press, 1982:108–11.
3. Reyntjes AJM, Heykants JJP, Woestenborghs RJH, Gelders YG, Aerts TJL. Pharmacokinetics of haloperidol decanoate: a 2-year follow-up. Int Pharmacopsychiat 1982, 17:238–46.
4. Deberdt R, Elens P, Berghmans W, Heykants J, Woestenborghs R, Driesens F, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiat Scand 1980;62:356–63.
5. Suy E, Woestenborghs R, Heykants J. Bioavailability and clinical effect of two different concentrations of haloperidol decanoate. Curr Ther Res 1982;31:982–91.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献